GGrantIndex
← Search

COMBINATION THERAPY W/ 1592U89, 141W94, &DMP 266 IN HIV

$241M01FY2000RRNIH

University Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Abstract

The purpose of this clinical study is to evaluate the safety and effectiveness of combination therapy with two investigational (experimental) drugs, 1592U89 and 141W94, and 1 FDA-approved drug, DMP-266 (Sustivea) in patients infected with HIV who have detectable levels of HIV virus in their blood even after combination therapy that included an HIV protease inhibitor.

View original record on NIH RePORTER →